A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis

Study Identifier
DE018
CT.gov Identifier
NCT00233571
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Rheumatoid Arthritis
    • Study Drug
  • Adalimumab 40 mg subcutaneous (SC) every other week (EOW)
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Completion of a previous D2E7 study - Subject is in good health (Investigator discretion) with a recent stable medical history
    Exclusion Criteria:
    - Former enrollment in this trial (DE018) - Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study - Female subject who is pregnant or breast feeding or considering becoming pregnant.

    Protocol Summary

    The purpose of the study is to assess the long-term safety and clinical efficacy of

    adalimumab in patients with rheumatoid arthritis

    Study Locations

    No locations found.